Epilepsy Market 2027 by Condition, Diagnosis and Treatment, End User | The Insight Partners

Epilepsy Market Forecast to 2027 - Covid-19 Impact and Global Analysis By Condition ( Epilepsy Drug Resistant/Intractable Epilepsy, Others ); Diagnosis and Treatment ( Imaging Devices, Blood Tests, Anti-Epileptic Drugs, Others ); End User ( Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others )

Report Code: TIPRE00016405 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Epilepsy is a central nervous system (neurological) disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness.

MARKET DYNAMICS

The epilepsy market is driving due to rising government funding for the development of new and effective drugs for the treatment of seizures. Moreover, various awareness programs conducted by organizations will further offer lucrative opportunities in the market in the review period.

MARKET SCOPE

The "Epilepsy Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of epilepsy market with detailed market segmentation by condition, diagnosis & treatment and end-user. The epilepsy market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in epilepsy market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The epilepsy market is segmented on the basis of condition, diagnosis & treatment and end-user. On the basis of condition, the market is segmented into epilepsy drug resistant/intractable epilepsy and others. On the basis of diagnosis & treatment, the market is segmented into imaging devices, blood tests, anti-epileptic drugs, and others. On the basis of end-user, the market is segmented into hospitals, clinics, ambulatory surgical centers, diagnostic centers, and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Epilepsy market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Epilepsy market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Epilepsy market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Epilepsy market in these regions.



Get more information on this report :

MARKET PLAYERS

The report covers key developments in the epilepsy market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from epilepsy market are anticipated to have lucrative growth opportunities in the future with the rising demand for epilepsy market in the global market. Below mentioned is the list of few companies engaged in the epilepsy market.

The report also includes the profiles of key players in epilepsy market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

- LivaNova PLC
- GlaxoSmithKline PLC
- Eisai Co. Ltd.
- Pfizer Inc.
- Medtronic PLC
- GW Pharmaceuticals PLC
- Novartis AG
- Johnson & Johnson Services Inc.
- Abbott Laboratories
- Becton Dickinson and Company

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.



Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Epilepsy Market - By Condition
1.3.2 Epilepsy Market - By Diagnosis and Treatment
1.3.3 Epilepsy Market - By End User
1.3.4 Epilepsy Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. EPILEPSY MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. EPILEPSY MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. EPILEPSY MARKET - GLOBAL MARKET ANALYSIS
6.1. EPILEPSY - GLOBAL MARKET OVERVIEW
6.2. EPILEPSY - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. EPILEPSY MARKET - REVENUE AND FORECASTS TO 2027 - CONDITION
7.1. OVERVIEW
7.2. CONDITION MARKET FORECASTS AND ANALYSIS
7.3. EPILEPSY DRUG RESISTANT/INTRACTABLE EPILEPSY
7.3.1. Overview
7.3.2. Epilepsy Drug Resistant/Intractable Epilepsy Market Forecast and Analysis
7.4. OTHERS
7.4.1. Overview
7.4.2. Others Market Forecast and Analysis
8. EPILEPSY MARKET - REVENUE AND FORECASTS TO 2027 - DIAGNOSIS AND TREATMENT
8.1. OVERVIEW
8.2. DIAGNOSIS AND TREATMENT MARKET FORECASTS AND ANALYSIS
8.3. IMAGING DEVICES
8.3.1. Overview
8.3.2. Imaging Devices Market Forecast and Analysis
8.4. BLOOD TESTS
8.4.1. Overview
8.4.2. Blood Tests Market Forecast and Analysis
8.5. ANTI-EPILEPTIC DRUGS
8.5.1. Overview
8.5.2. Anti-Epileptic Drugs Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. EPILEPSY MARKET - REVENUE AND FORECASTS TO 2027 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. CLINICS
9.4.1. Overview
9.4.2. Clinics Market Forecast and Analysis
9.5. AMBULATORY SURGICAL CENTERS
9.5.1. Overview
9.5.2. Ambulatory Surgical Centers Market Forecast and Analysis
9.6. DIAGNOSTIC CENTERS
9.6.1. Overview
9.6.2. Diagnostic Centers Market Forecast and Analysis
9.7. OTHERS
9.7.1. Overview
9.7.2. Others Market Forecast and Analysis
10. EPILEPSY MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Epilepsy Market Overview
10.1.2 North America Epilepsy Market Forecasts and Analysis
10.1.3 North America Epilepsy Market Forecasts and Analysis - By Condition
10.1.4 North America Epilepsy Market Forecasts and Analysis - By Diagnosis and Treatment
10.1.5 North America Epilepsy Market Forecasts and Analysis - By End User
10.1.6 North America Epilepsy Market Forecasts and Analysis - By Countries
10.1.6.1 United States Epilepsy Market
10.1.6.1.1 United States Epilepsy Market by Condition
10.1.6.1.2 United States Epilepsy Market by Diagnosis and Treatment
10.1.6.1.3 United States Epilepsy Market by End User
10.1.6.2 Canada Epilepsy Market
10.1.6.2.1 Canada Epilepsy Market by Condition
10.1.6.2.2 Canada Epilepsy Market by Diagnosis and Treatment
10.1.6.2.3 Canada Epilepsy Market by End User
10.1.6.3 Mexico Epilepsy Market
10.1.6.3.1 Mexico Epilepsy Market by Condition
10.1.6.3.2 Mexico Epilepsy Market by Diagnosis and Treatment
10.1.6.3.3 Mexico Epilepsy Market by End User
10.2. EUROPE
10.2.1 Europe Epilepsy Market Overview
10.2.2 Europe Epilepsy Market Forecasts and Analysis
10.2.3 Europe Epilepsy Market Forecasts and Analysis - By Condition
10.2.4 Europe Epilepsy Market Forecasts and Analysis - By Diagnosis and Treatment
10.2.5 Europe Epilepsy Market Forecasts and Analysis - By End User
10.2.6 Europe Epilepsy Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Epilepsy Market
10.2.6.1.1 Germany Epilepsy Market by Condition
10.2.6.1.2 Germany Epilepsy Market by Diagnosis and Treatment
10.2.6.1.3 Germany Epilepsy Market by End User
10.2.6.2 France Epilepsy Market
10.2.6.2.1 France Epilepsy Market by Condition
10.2.6.2.2 France Epilepsy Market by Diagnosis and Treatment
10.2.6.2.3 France Epilepsy Market by End User
10.2.6.3 Italy Epilepsy Market
10.2.6.3.1 Italy Epilepsy Market by Condition
10.2.6.3.2 Italy Epilepsy Market by Diagnosis and Treatment
10.2.6.3.3 Italy Epilepsy Market by End User
10.2.6.4 Spain Epilepsy Market
10.2.6.4.1 Spain Epilepsy Market by Condition
10.2.6.4.2 Spain Epilepsy Market by Diagnosis and Treatment
10.2.6.4.3 Spain Epilepsy Market by End User
10.2.6.5 United Kingdom Epilepsy Market
10.2.6.5.1 United Kingdom Epilepsy Market by Condition
10.2.6.5.2 United Kingdom Epilepsy Market by Diagnosis and Treatment
10.2.6.5.3 United Kingdom Epilepsy Market by End User
10.2.6.6 Rest of Europe Epilepsy Market
10.2.6.6.1 Rest of Europe Epilepsy Market by Condition
10.2.6.6.2 Rest of Europe Epilepsy Market by Diagnosis and Treatment
10.2.6.6.3 Rest of Europe Epilepsy Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Epilepsy Market Overview
10.3.2 Asia-Pacific Epilepsy Market Forecasts and Analysis
10.3.3 Asia-Pacific Epilepsy Market Forecasts and Analysis - By Condition
10.3.4 Asia-Pacific Epilepsy Market Forecasts and Analysis - By Diagnosis and Treatment
10.3.5 Asia-Pacific Epilepsy Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Epilepsy Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Epilepsy Market
10.3.6.1.1 Australia Epilepsy Market by Condition
10.3.6.1.2 Australia Epilepsy Market by Diagnosis and Treatment
10.3.6.1.3 Australia Epilepsy Market by End User
10.3.6.2 China Epilepsy Market
10.3.6.2.1 China Epilepsy Market by Condition
10.3.6.2.2 China Epilepsy Market by Diagnosis and Treatment
10.3.6.2.3 China Epilepsy Market by End User
10.3.6.3 India Epilepsy Market
10.3.6.3.1 India Epilepsy Market by Condition
10.3.6.3.2 India Epilepsy Market by Diagnosis and Treatment
10.3.6.3.3 India Epilepsy Market by End User
10.3.6.4 Japan Epilepsy Market
10.3.6.4.1 Japan Epilepsy Market by Condition
10.3.6.4.2 Japan Epilepsy Market by Diagnosis and Treatment
10.3.6.4.3 Japan Epilepsy Market by End User
10.3.6.5 South Korea Epilepsy Market
10.3.6.5.1 South Korea Epilepsy Market by Condition
10.3.6.5.2 South Korea Epilepsy Market by Diagnosis and Treatment
10.3.6.5.3 South Korea Epilepsy Market by End User
10.3.6.6 Rest of Asia-Pacific Epilepsy Market
10.3.6.6.1 Rest of Asia-Pacific Epilepsy Market by Condition
10.3.6.6.2 Rest of Asia-Pacific Epilepsy Market by Diagnosis and Treatment
10.3.6.6.3 Rest of Asia-Pacific Epilepsy Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Epilepsy Market Overview
10.4.2 Middle East and Africa Epilepsy Market Forecasts and Analysis
10.4.3 Middle East and Africa Epilepsy Market Forecasts and Analysis - By Condition
10.4.4 Middle East and Africa Epilepsy Market Forecasts and Analysis - By Diagnosis and Treatment
10.4.5 Middle East and Africa Epilepsy Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Epilepsy Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Epilepsy Market
10.4.6.1.1 South Africa Epilepsy Market by Condition
10.4.6.1.2 South Africa Epilepsy Market by Diagnosis and Treatment
10.4.6.1.3 South Africa Epilepsy Market by End User
10.4.6.2 Saudi Arabia Epilepsy Market
10.4.6.2.1 Saudi Arabia Epilepsy Market by Condition
10.4.6.2.2 Saudi Arabia Epilepsy Market by Diagnosis and Treatment
10.4.6.2.3 Saudi Arabia Epilepsy Market by End User
10.4.6.3 U.A.E Epilepsy Market
10.4.6.3.1 U.A.E Epilepsy Market by Condition
10.4.6.3.2 U.A.E Epilepsy Market by Diagnosis and Treatment
10.4.6.3.3 U.A.E Epilepsy Market by End User
10.4.6.4 Rest of Middle East and Africa Epilepsy Market
10.4.6.4.1 Rest of Middle East and Africa Epilepsy Market by Condition
10.4.6.4.2 Rest of Middle East and Africa Epilepsy Market by Diagnosis and Treatment
10.4.6.4.3 Rest of Middle East and Africa Epilepsy Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Epilepsy Market Overview
10.5.2 South and Central America Epilepsy Market Forecasts and Analysis
10.5.3 South and Central America Epilepsy Market Forecasts and Analysis - By Condition
10.5.4 South and Central America Epilepsy Market Forecasts and Analysis - By Diagnosis and Treatment
10.5.5 South and Central America Epilepsy Market Forecasts and Analysis - By End User
10.5.6 South and Central America Epilepsy Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Epilepsy Market
10.5.6.1.1 Brazil Epilepsy Market by Condition
10.5.6.1.2 Brazil Epilepsy Market by Diagnosis and Treatment
10.5.6.1.3 Brazil Epilepsy Market by End User
10.5.6.2 Argentina Epilepsy Market
10.5.6.2.1 Argentina Epilepsy Market by Condition
10.5.6.2.2 Argentina Epilepsy Market by Diagnosis and Treatment
10.5.6.2.3 Argentina Epilepsy Market by End User
10.5.6.3 Rest of South and Central America Epilepsy Market
10.5.6.3.1 Rest of South and Central America Epilepsy Market by Condition
10.5.6.3.2 Rest of South and Central America Epilepsy Market by Diagnosis and Treatment
10.5.6.3.3 Rest of South and Central America Epilepsy Market by End User
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL EPILEPSY MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. EPILEPSY MARKET, KEY COMPANY PROFILES
13.1. LIVANOVA PLC
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. GLAXOSMITHKLINE PLC
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. EISAI CO. LTD.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. PFIZER INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. MEDTRONIC PLC
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. GW PHARMACEUTICALS PLC
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. NOVARTIS AG
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. JOHNSON AND JOHNSON SERVICES INC.
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. ABBOTT LABORATORIES
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. BECTON DICKINSON AND COMPANY
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. LivaNova PLC
2. GlaxoSmithKline PLC
3. Eisai Co. Ltd.
4. Pfizer Inc.
5. Medtronic PLC
6. GW Pharmaceuticals PLC
7. Novartis AG
8. Johnson & Johnson Services Inc.
9. Abbott Laboratories
10. Becton Dickinson and Company

TIPRE00016405
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking